Center for Research in Security Prices, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Increasing the Reach of Promising Dropout Prevention Programs: Examining the Trade-offs Between Scale and Effectiveness

Not Applicable

Conditions: Educational Achievement

Interventions: Other: SAGA Innovations
Other: Scale-up tutors
Other: Standard Tutors

First Posted Date: 2016-09-05

Last Posted Date: 2020-04-24

Lead Sponsor: University of Chicago

Target Recruit Count: 6600

Registration Number: NCT02889640

Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation

Phase 4

Completed

Conditions: Smoking Cessation
Alcohol Drinking

Interventions: Drug: Chantix
Behavioral: Behavioral Counseling Sessions
Drug: NicodermCQ
Drug: Placebo

First Posted Date: 2016-08-08

Last Posted Date: 2021-09-27

Lead Sponsor: University of Chicago

Target Recruit Count: 122

Registration Number: NCT02859142

Locations: 🇺🇸
Clinical Addictions Research Laboratory, Chicago, Illinois, United States

A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients

Phase 2

Withdrawn

Conditions: Parkinson's Disease

Interventions: Drug: Duloxetine
Drug: Donepezil
Drug: Modafinil

First Posted Date: 2016-08-05

Last Posted Date: 2017-12-12

Lead Sponsor: University of Chicago

Registration Number: NCT02857244

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

Milk Thistle in Body Dysmorphic Disorder

Phase 2

Withdrawn

Conditions: Body Dysmorphic Disorder

Interventions: Drug: Placebo
Drug: Milk Thistle

First Posted Date: 2016-07-25

Last Posted Date: 2022-12-28

Lead Sponsor: University of Chicago

Registration Number: NCT02843451

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study

Phase 2

Active, not recruiting

Conditions: Head and Neck Cancer
Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Placebo
Drug: Pembrolizumab

First Posted Date: 2016-07-22

Last Posted Date: 2024-05-13

Lead Sponsor: University of Chicago

Target Recruit Count: 100

Registration Number: NCT02841748

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 1 locations

Effects of Pregnenolone on Perceived Social Isolation

Phase 2

Terminated

Conditions: Perceived Social Isolation

Interventions: Drug: Pregnenolone 175mg
Drug: Placebo
Drug: Pregnenolone 400mg

First Posted Date: 2016-07-11

Last Posted Date: 2024-05-16

Lead Sponsor: University of Chicago

Target Recruit Count: 34

Registration Number: NCT02826577

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Thirty Million Words- Well Baby Initiative

Not Applicable

Completed

Conditions: Behavior
Communication
Language

Interventions: Behavioral: Thirty Million Words- Well Baby
Other: Safety Starts at Home

First Posted Date: 2016-06-23

Last Posted Date: 2020-03-24

Lead Sponsor: University of Chicago

Target Recruit Count: 952

Registration Number: NCT02812017

Locations: 🇺🇸
Lawndale Christian Health Center - Archer Avenue, Chicago, Illinois, United States
🇺🇸
Advocate Medical Group, Chicago, Illinois, United States
🇺🇸
Lawndale Christian Health Center, Chicago, Illinois, United States

and more 5 locations

Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Other: Placebo
Drug: Mifepristone
Drug: Nab-Paclitaxel

First Posted Date: 2016-06-02

Last Posted Date: 2024-12-09

Lead Sponsor: University of Chicago

Target Recruit Count: 29

Registration Number: NCT02788981

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Northshore University HealthSystem, Evanston, Illinois, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 2 locations

Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study

Phase 1

Terminated

Conditions: Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions: Drug: FOLFIRINOX (oxaliplatin, leucovorin, irinotecan)

First Posted Date: 2016-05-25

Last Posted Date: 2019-03-19

Lead Sponsor: University of Chicago

Target Recruit Count: 1

Registration Number: NCT02782182

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Pilot Study to Compare Fresh Frozen Plasma With 24-Hour Plasma in Babies Up to Age Six Months

Phase 4

Withdrawn

Conditions: Blood Coagulation Disorders

Interventions: Biological: Plasma

First Posted Date: 2016-05-17

Last Posted Date: 2018-10-24

Lead Sponsor: University of Chicago

Registration Number: NCT02774317

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy